Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Dual Site-dual Channel Non-invasive Brain Stimulation for Language and Cognitive Function in Stroke Patients
Not Applicable
Completed
- Conditions
- Cognitive ImpairmentStrokeAphasia
- Interventions
- Device: IFG stimulationDevice: DLPFC stimulationBehavioral: aphasia therapy
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03486782
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Effect of Wearable Hip-Assist Robot on Reduction of Cardiopulmonary Metabolic Efficiency in Healthy Adults
Not Applicable
Completed
- Conditions
- Gait
- Interventions
- Device: Treadmill walking
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT03484624
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Resting-state Functional Connectivity Changes During Migraine Treatment
Withdrawn
- Conditions
- Migraine Disorders
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT03484871
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Liquid Biopsy in Lung Cancer
Completed
- Conditions
- Circulating Tumor CellLung Cancer (Diagnosis)
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 111
- Registration Number
- NCT03479099
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Data Collection for Motor Function and Gait Pattern Analysis of Patients With Chronic Stroke
Completed
- Conditions
- Chronic Stroke
- Interventions
- Other: Chronic stroke
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT03468166
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Therapeutic Effects of Endoscopic Ablation of Hunner Lesions in Interstitial Cystitis/ Bladder Pain Syndrome Patients
Recruiting
- Conditions
- Interstitial Cystitis
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 500
- Registration Number
- NCT03468530
- Locations
- 🇰🇷
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
Not Applicable
Completed
- Conditions
- Interstitial Cystitis
- Interventions
- Drug: Hyaluronic Acid and Chondroitin Sulfate
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 62
- Registration Number
- NCT03463499
- Locations
- 🇰🇷
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Most Effective Stimulation Site in Transcranial Direct Current Stimulation for Gait Recovery After Stoke
Not Applicable
Completed
- Conditions
- Gait Disorders, NeurologicStroke
- Interventions
- Device: Ipsilesional stimulationOther: Walking on treadmillDevice: Contralesional stimulation
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT03460886
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate
Completed
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 432
- Registration Number
- NCT03460873
- Locations
- 🇰🇷
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
Phase 2
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Durvalumab Plus Tremelimumab
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT03450967
- Locations
- 🇰🇷
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath